siRNA: A Promising New Tool for Future Breast Cancer Therapy

Abstract

Breast cancer remains a major health concern as it continues to be both the leading cause of cancer-related deaths and most commonly diagnosed form of cancer among women. Recently, RNAi (RNA interference)-based gene therapy has gained attention for its sequence-specific mechanism of gene silencing. RNAi may be induced with the use of short interfering RNAs (siRNAs), which are generated from double-stranded RNA (dsRNA) precursors. Although siRNA has its limitations, siRNA shows enormous potential as a promising tool for the regulation of disease-associated genes, including oncogenes and tumor suppressor genes. In this review, we will discuss the approaches, implications, and challenges of siRNA-mediated RNAi gene therapy regarding various targets of breast cancer.

Lipid‑based nanoparticles for the therapeutic delivery of non‑coding RNAs in breast cancer (Review)

“…The encapsulated ncRNAs within cationic liposomes exhibit a preferential uptake from the target cells through endocytosis. To further ensure that the desired cells are targeted, ligands binding to cell surface receptors of the target tissue are incorporated into the cationic coat of the liposome (24). The engineering of carriers has gained considerable attention in recent years due to the development of effective delivery systems that transport small interfering RNAs (siRNAs) and microRNAs (miRNAs/miRs) into the tumor tissues and the cytoplasm of tumor cells.…”

Advances with Lipid-Based Nanosystems for siRNA Delivery to Breast Cancers

“…The incorporated siRNAs within cationic liposomes demonstrate a superior uptake by the target cells through endocytosis. To target the desired cells effectively, ligand binding to the cell surface receptors of target cells was merged with the cationic coat of the liposome [ 35 ]. The fabrication of lipid-based nanocarriers has received much consideration due to the progress of systems for delivering siRNA to the cytoplasm of the tumor cells, protecting them from the circulatory environment that provides resistance to nucleases, overcoming immune responses enabling sufficient delivery to cancer cells [ 36 ].…”